{{Drugbox
| IUPAC_name = (4''R'',5''S'',6''S'')-(Pivaloyloxy)methyl 3-((1-(4,5-dihydrothiazol-2-yl)azetidin-3-yl)thio)-6-((''R'')-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
| image = Tebipenem pivoxil2DCSD.svg
| caption = Tebipenem pivoxil

<!--Clinical data-->
| tradename = Orapenem
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = 
| legal_status = Prescription-only in Japan; investigational elsewhere
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = 
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 161715-24-8
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 
| PDB_ligand = 1TE
| KEGG = D09598

<!--Chemical data-->
| C=22 | H=31 | N=3 | O=6 | S=2 
| molecular_weight = 497.63 g/mol
| smiles = [H][C@]12N(C(C(OCOC(C(C)(C)C)=O)=O)=C(SC3CN(C4=NCCS4)C3)[C@@H]2C)C([C@@]1([C@H](O)C)[H])=O
}}

'''Tebipenem''' (brand name: '''Orapenem''') is a [[broad-spectrum antibiotic|broad-spectrum]] orally-administered [[antibiotic]], from the [[carbapenem]] subgroup of [[β-lactam antibiotic]]s. It was developed as a replacement drug to combat bacteria that had acquired [[antibiotic resistance]] to commonly used antibiotics.<ref>{{Cite journal 
| last1 = El-Gamal | first1 = M. I. 
| last2 = Oh | first2 = C. H. 
| title = Current status of carbapenem antibiotics 
| journal = Current topics in medicinal chemistry 
| volume = 10 
| issue = 18 
| pages = 1882–1897 
| year = 2010 
| pmid = 20615191
 | doi=10.2174/156802610793176639
}}</ref><ref>{{Cite journal 
| last1 = Fujimoto | first1 = K. 
| last2 = Takemoto | first2 = K. 
| last3 = Hatano | first3 = K. 
| last4 = Nakai | first4 = T. 
| last5 = Terashita | first5 = S. 
| last6 = Matsumoto | first6 = M. 
| last7 = Eriguchi | first7 = Y. 
| last8 = Eguchi | first8 = K. 
| last9 = Shimizudani | first9 = T. 
| doi = 10.1128/AAC.01051-12 
| last10 = Sato | first10 = K. 
| last11 = Kanazawa | first11 = K. 
| last12 = Sunagawa | first12 = M. 
| last13 = Ueda | first13 = Y. 
| title = Novel Carbapenem Antibiotics for Parenteral and Oral Applications: In Vitro and in Vivo Activities of 2-Aryl Carbapenems and Their Pharmacokinetics in Laboratory Animals 
| journal = Antimicrobial Agents and Chemotherapy 
| volume = 57 
| issue = 2 
| pages = 697–707 
| year = 2012 
| pmid = 23147735 
| pmc =3553697 
}}</ref> Tebipenem is formulated as the [[ester]] '''tebipenem pivoxil''' due to the better absorption and improved [[bioavailability]] of this form.<ref>{{Cite journal 
| last1 = Kato | first1 = K. 
| last2 = Shirasaka | first2 = Y. 
| last3 = Kuraoka | first3 = E. 
| last4 = Kikuchi | first4 = A. 
| last5 = Iguchi | first5 = M. 
| last6 = Suzuki | first6 = H. 
| last7 = Shibasaki | first7 = S. 
| last8 = Kurosawa | first8 = T. 
| last9 = Tamai | first9 = I. 
| doi = 10.1021/mp100130b 
| title = Intestinal Absorption Mechanism of Tebipenem Pivoxil, a Novel Oral Carbapenem: Involvement of Human OATP Family in Apical Membrane Transport 
| journal = Molecular Pharmaceutics 
| volume = 7 
| issue = 5 
| pages = 1747–1756 
| year = 2010 
| pmid = 20735088 
| pmc = 
}}</ref> It has performed well in [[clinical trial]]s for ear infection and looks likely to be further developed in future.<ref>{{Cite journal 
| last1 = Sugita | first1 = R. 
| title = Good transfer of tebipenem into middle ear effusion conduces to the favorable clinical outcomes of tebipenem pivoxil in pediatric patients with acute otitis media 
| doi = 10.1007/s10156-012-0513-5 
| journal = Journal of Infection and Chemotherapy 
| volume = 19 
| issue = 3 
| pages = 465–471 
| year = 2013 
| pmid = 23393013 
| pmc = 
}}</ref> It is only marketed in [[Japan]].<ref>{{cite web|title=Tebipenem Pivoxil|date=7 August 2014|accessdate=6 April 2015|url = https://www.medicinescomplete.com/mc/martindale/current/20642-e.htm | location = London, UK | publisher = Pharmaceutical Press | work = Martindale: The Complete Drug Reference|editor = Rossi, S}}</ref> Tebipenem is the first carbapenem whose [[prodrug]] form, the pivalyl ester, is orally available.<ref>{{cite journal|last = Hazra | first = S | author2 = Xu, H | author3 = Blanchard, J | title = Tebipenem, a New Carbapenem Antibiotic is a Slow Substrate that Inhibits the β-Lactamase from Mycobacterium tuberculosis | journal = Biochemistry |doi = 10.1021/bi500339j | volume = 53 | issue = 22  | pages = 3671–3678 | date = June 2014 | url = https://www.researchgate.net/profile/Saugata_Hazra3/publication/262533324_Tebipenem_a_New_Carbapenem_Antibiotic_Is_a_Slow_Substrate_That_Inhibits_the_beta-Lactamase_from_Mycobacterium_tuberculosis/links/0f3175389d3c4692ba000000.pdf?ev=pub_int_doc_dl&origin=publication_detail&inViewer=true |pmid = 24846409 | pmc=4053071}}</ref>

==References==
<references/>

{{CephalosporinAntiBiotics}}

[[Category:Carbapenem antibiotics]]
[[Category:Prodrugs]]
[[Category:Thiazolines]]